
The panel shares at what point they decide to start treatment for patients with lower-risk MDS and symptomatic anemia.

Your AI-Trained Oncology Knowledge Connection!


The panel shares at what point they decide to start treatment for patients with lower-risk MDS and symptomatic anemia.

Yazan Madanat, MD, details the available options for first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.

Hetty Carraway, MD, reviews how MDS is diagnosed and the common symptoms that patients who have MDS may present with.